drugset
drugset / Trial / NCT02716987

Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

NCT02716987 ↗

Phase 1 Completed 20 enrolled Neurocrine Biosciences Takeda · collab
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine the relationship between TAK-831 dose, plasma exposure, extent and duration of brain D-amino acid oxidase (DAO) enzyme occupancy following single oral dosing of TAK-831 in healthy participants.

Timeline

Start
2016-03-21
Primary completion
2016-08-30
Completion
2016-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Luvadaxistat Small molecule 100 mg Oral
Subject Luvadaxistat Small molecule 200 mg Oral
Subject Luvadaxistat Small molecule 250 mg Oral
Subject Luvadaxistat Small molecule 500 mg Oral
Subject [18F]PGM299 Diagnostic / imaging agent 12.5 ug —
Subject [18F]PGM299 Diagnostic / imaging agent 100 mbq —

Indications

No indication recorded.